Fresenius And Formycon Strike Stelara Settlement For Europe And Canada

Agreement With J&J Clears Path For Partners To Launch Ustekinumab Biosimilar

 
• By Dave Wallace

Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.

EU and Canadian flags, mixed
European and Canadian launches can proceed under the settlement • Source: Shutterstock

More from Deals

More from Business